ArticleCell research2018
Anti-PD1 in the wonder-gut-land.
Article in Cell research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Killing cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma.Oncoimmunology · 2026Review
- Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk-Stratified Analysis.Journal of clinical medicine · 2026Article
- The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer.International journal of molecular sciences · 2024Review
- Review
- Bladder cancer, inflammageing and microbiomes.Nature reviews. Urology · 2022Review
- Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.Aging · 2022Review
- Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma.Frontiers in molecular biosciences · 2022Review
- Treatment of inflammatory bowel disease: Potential effect of NMN on intestinal barrier and gut microbiota.Current research in food science · 2022Article
- Inhibition of PD-1 Protects against TNBS-Induced Colitis via Alteration of Enteric Microbiota.BioMed research international · 2021Article
- Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?Nature reviews. Immunology · 2020Article
- Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.International journal of molecular sciences · 2020Review
- Pulmonary Micro-Ecological Changes and Potential Microbial Markers in Lung Cancer Patients.Frontiers in oncology · 2020Review
- Antibiotics, cancer risk and oncologic treatment efficacy: a practical review of the literature.Ecancermedicalscience · 2020Review
- The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer.International journal of molecular sciences · 2019Review
- Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.Digestive diseases and sciences · 2018Article
- Pushing the Limits of Cancer Therapy: The Nutrient Game.Frontiers in oncology · 2018Article
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
Abstract
After the initial success of cancer immunotherapy using immune checkpoint blockers, the challenge is to understand why only a minority of patients respond to the therapy and to increase the rate of response. Three recent papers now report that the gut microbiota modulates the response to anti-PD1 therapy in patients with epithelial cancers or melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.